sorafenib
bayer
[]
source is a phase 3 trial looking at adjuvant rx for resectable ahcc, sorafenib + tace vs sorafenib. improved outcomes in pts w/ portal thrombosis . improved rfs ans overall survival! #gi23 #gicancer #cancerresearch 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"